WRLD A.LIVE

02:001 report

• Gaps identified in surveillance of incidental lung nodules AuntMinnie

23:001 report

• Real-World Data Support Outpatient Tarlatamab for Community SCLC Care Targeted Oncology

22:00nothing heard

21:00nothing heard

20:00nothing heard

19:00nothing heard

18:00nothing heard

17:00nothing heard

16:00nothing heard

15:00nothing heard

14:00nothing heard

13:00nothing heard

12:00nothing heard

11:00nothing heard

10:00nothing heard

09:00nothing heard

08:00nothing heard

07:00nothing heard

06:00nothing heard

05:00nothing heard

04:001 report

• 10 Strategies to Increase Radon Testing and Prevent Lung Cancer Respiratory Therapy

03:00nothing heard

02:002 reports

• Blood test offers new way to track lung cancer Medical Xpress
• Beyond BMI: Unraveling the Obesity Paradox in Lung Cancer Targeted Oncology

19:002 reports

• Gamma-delta T cells destroyed SCLC in the laboratory — ScienceAlert UA.NEWS
• An Overlooked Immune Cell Killed The Deadliest Form of Lung Cancer in Lab Tests ScienceAlert

18:00nothing heard

17:00nothing heard

16:00nothing heard

15:00nothing heard

14:00nothing heard

13:00nothing heard

12:00nothing heard

11:00nothing heard

10:00nothing heard

09:00nothing heard

08:00nothing heard

07:00nothing heard

06:00nothing heard

05:00nothing heard

04:00nothing heard

03:00nothing heard

02:00nothing heard

01:00nothing heard

00:001 report

• Data Support Real-World Benefit of Cemiplimab in Advanced NSCLC Care CancerNetwork

23:002 reports

• Preliminary SARON results: radiotherapy extended progression-free period by 56% — News-Medical UA.NEWS
• Radiation Added to Systemic Therapy Improves PFS But Not OS for Oligometastatic NSCLC The ASCO Post

22:001 report

• Why Never-Smoking Asian Women Skip Annual Lung Cancer Screening EMJ

21:00nothing heard

20:00nothing heard

19:00nothing heard

18:00nothing heard

17:00nothing heard

16:00nothing heard

15:002 reports

• Tom Newsom-Davis։ Does Adding Radiotherapy to SACT Improve Survival in Synchronous Oligometastatic NSCLC? Oncodaily
• Patients with a form of advanced lung cancer lived 56 percent longer without their disease progressing after receiving radiotherapy in addition to standard treatment News-Medical

14:00nothing heard

13:00nothing heard

12:00nothing heard

11:00nothing heard

10:00nothing heard

09:00nothing heard

08:00nothing heard

07:004 reports

• Understanding the Stigma of Lung Cancer University of Pittsburgh Medical Center
• Why non-smokers still develop lung cancer Türkiye Today
• Jill Feldman: After 25 Years of Awareness, Are We Changing Minds About Lung Cancer? Oncodaily
• Beyond cigarettes: Uncovering the causes of lung cancer in nonsmokers The Spokesman-Review

06:001 report

• Lung Cancer Blood Test May Help Predict Treatment Outcomes Before Surgery Inside Precision Medicine

05:00nothing heard

04:00nothing heard

03:005 reports

• Liquid biopsy reliably detects early-stage lung cancer recurrence risk News-Medical
• Sucharu Prakash: Turning MRD Detection Into Actionable Clinical Decisions Oncodaily
• New Blood Test Can Find One of the Deadliest Cancers Returning—Before Scans Newsweek
• Prototype Assay Targets Early Stage Lung Cancer Detection With Circulating Biomarker Data at ESMO GenomeWeb
• MDT-BRIDGE: Early ctDNA Clearance Predicts Pathological Response and Favorable Outcomes in Stage II–III NSCLC Oncodaily

02:00nothing heard

01:00nothing heard

00:002 reports

• Metabolic vulnerability identified in small cell lung cancer Medical Xpress
• Beyond cigarettes: Uncovering the causes of lung cancer in nonsmokers The Detroit News

10:001 report

• Key Takeaways From DeLLphi-305 at ESMO 2026 Targeted Oncology

09:002 reports

• Advanced lung cancer patients benefit from radiotherapy in addition to standard treatment The Institute of Cancer Research
• Cancer breakthrough as 'added treatment' controls disease for longer Wales Online

08:00nothing heard

07:00nothing heard

06:001 report

• Tarlatamab Maintenance Combo Boosts Lung Cancer Survival Medscape

05:001 report

• ESMO Spotlight: Amgen's Imdelltra steals the show with unprecedented data in small-cell lung cancer FirstWord Pharma

04:00nothing heard

03:00nothing heard

02:00nothing heard

01:005 reports

• Aadil Najeed։ SARON Trial Shows Improved PFS and Local Disease Control With Consolidation Radiotherapy in NSCLC Oncodaily
• New trial finds 'added treatment' keeps advanced cancer under control for longer Cornwall Live
• Cancer breakthrough as 'added treatment' controls disease for longer Surrey Live
• Radiotherapy ‘could keep advanced lung cancer patients stable for longer’ LBC
• SARON: Consolidation Radiotherapy Improves PFS but Not Overall Survival in Oligometastatic NSCLC Oncodaily

00:001 report

• Lung Surgery Assessment Considers Psychological Reserve and Nutrition EMJ

23:001 report

• Another Unprecedented OS Win in Extensive-Stage SCLC With Tarlatamab Maintenance MedPage Today

22:001 report

• ctDNA clearance and outcomes for resectable lung cancer from NeoCOAST-2 Nature

21:00nothing heard

20:00nothing heard

19:00nothing heard

18:00nothing heard

17:00nothing heard

16:00nothing heard

15:001 report

• Tom John: Jacob Sands Receives a Standing Ovation for DeLLphi-305 at ESMO 2026 Oncodaily

14:00nothing heard

13:00nothing heard

12:00nothing heard

11:00nothing heard

10:00nothing heard

09:00nothing heard

08:00nothing heard

07:00nothing heard

06:001 report

• Imfinzi plus Imdelltra reduced the risk of death by 58% in 1st-line extensive-stage small cell lung cancer in the DeLLphi-305 Phase III trial AstraZeneca

05:00nothing heard

04:001 report

• Nabil Ismaili: ESMO26 Highlights Major Survival Gains With Tarlatamab Plus Durvalumab Oncodaily

03:001 report

• Lung cancer breakthrough: drug combination cuts death risk by 58% in major trial Ynetnews

02:001 report

• DeLLphi-305 Data Support Frontline Maintenance Tarlatamab Plus Durvalumab as a New SOC in ES-SCLC OncLive

01:00nothing heard

00:005 reports

• Tarlatamab Maintenance Combo Extends Survival in Extensive-Stage SCLC CancerNetwork
• Aakash Desai: ESMO26 Presidential Symposium Presents Practice-Changing DeLLphi-305 Results Oncodaily
• Amgen's Imdelltra combo more than halves risk of death in small cell lung cancer Endpoints News
• IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER Amgen
• Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer CNBC

23:006 reports

• Amgen, Astra Drug Duo Boosts Survival for Deadly Lung Cancer Bloomberg
• ESMO: Amgen’s Imdelltra drives massive survival benefit in ‘watershed moment’ for small cell lung cancer Fierce Pharma
• ‘Practice-changing’ new lung cancer immunotherapy improves survival NBC News
• IMFINZI® (durvalumab) plus tarlatamab-dlle reduced the risk of death by 58% in 1st-line extensive-stage small cell lung cancer in the DeLLphi-305 Phase III trial Business Wire
• Amgen drug combined with immunotherapy extends survival in lung cancer trial Reuters
• CROWN: ctDNA Analyses Help Predict Early Progression With First-Line Lorlatinib in ALK+ NSCLC OncLive

22:00nothing heard

21:00nothing heard

20:00nothing heard

19:00nothing heard

18:001 report

• CROWN: ctDNA Analysis Identifies Genomic Features Linked to Early Lorlatinib Progression in ALK+ NSCLC Oncodaily

17:001 report

• DESTINY-Lung04: T-DXd Delays Pulmonary Symptom Deterioration Without Greater Overall Treatment Bother in HER2-Mutant NSCLC Oncodaily

16:00nothing heard

15:00nothing heard

14:00nothing heard

13:001 report

• VDAC1 regulates disulfidptosis susceptibility and associates with the immune microenvironment via multi-omics analysis in lung adenocarcinoma Nature

12:00nothing heard

11:00nothing heard

10:00nothing heard

09:00nothing heard

08:00nothing heard

07:00nothing heard

06:00nothing heard

05:00nothing heard

04:00nothing heard

03:00nothing heard

02:00nothing heard

01:001 report

• The top​ 5 cause​s of lung cancer in non-smokers​ - and how to limit your risk The Independent

00:001 report

• ‘Lung cancer can happen to anyone’: San Antonio nonsmoker raises awareness after diagnosis KSAT

23:006 reports

• ESMO 2026: Cancer vaccine stops melanoma returning and a targeted drug slows advanced stomach cancer - Cancer Research UK Cancer News
• Dana-Farber Presents Phase 3 Lung Cancer Data in ESMO Presidential Symposium | Newswise Newswise
• Dana-Farber Presents Phase 3 Lung Cancer Data in ESMO Presidential Symposium [IMAGE] EurekAlert!
• Gilberto Lopes: 5 Lung Cancer Trials I Will be Watching Closely at ESMO26 Oncodaily
• ESMO 2026: The Presentations That May Transform The Lung Cancer Paradigm CancerNetwork
• Polls Reveal Top Picks for Lung Cancer Abstracts of Interest at ESMO 2026 OncLive

22:00nothing heard

21:00nothing heard

20:001 report

• Persistent cough leads to healthy woman’s lung cancer diagnosis multicare.org

19:00nothing heard

18:003 reports

• Lung Cancer in Nonsmokers: Rising Among Women and Younger Adults GreaterGood
• Eric K. Singhi, M.D., on lung cancer among younger adults Managed Healthcare Executive
• Beyond cigarettes: Uncovering the causes of lung cancer in nonsmokers The Washington Post

17:00nothing heard

16:00nothing heard

15:00nothing heard

14:00nothing heard

13:001 report

• Unlocking the body’s secret weapon against lung cancer The Times of India

12:001 report

• Scientists discover a hidden immune weapon against deadly lung cancer Science Daily

11:00nothing heard

10:00nothing heard

09:00nothing heard

08:003 reports

• Invisible no more: New treatment avenue unlocked for deadliest lung cancer News-Medical
• γδ T cells expose hidden immune vulnerability in small-cell lung cancer BioWorld News
• Scientists discover a hidden immune weapon against deadly lung cancer Science Daily

07:00nothing heard

06:00nothing heard

05:00nothing heard

04:00nothing heard

03:00nothing heard

02:003 reports

• What’s New On Radiotherapy of Lung Cancer in 2026? Oncodaily
• Breath Hold Not Linked to Better Lung Lesion Biopsy Yield MedPage Today
• ASCO 2026: Lung Cancer Specialist Apar Kishor Ganti, MD, Shares His Insights The ASCO Post

19:001 report

• Anti-Inflammatory Compound From Citrus Slows Lung Cancer Growth Technology Networks

18:00nothing heard

17:00nothing heard

16:00nothing heard

15:00nothing heard

14:00nothing heard

13:00nothing heard

12:00nothing heard

11:00nothing heard

10:00nothing heard

09:00nothing heard

08:00nothing heard

07:00nothing heard

06:00nothing heard

05:001 report

• PLA2G4A-driven arachidonic acid metabolic reprogramming promotes NSCLC progression via the HSF1 signaling axis Nature

04:001 report

• Reducing Stigma and Nihilism Around Lung Cancer Screening and Diagnosis CancerNetwork

03:00nothing heard

02:001 report

• Dana-Farber Presents Phase 3 Lung Cancer Data in ESMO Presidential Symposium FirstWord Pharma

01:002 reports

• Katsuaki Maehara։ Patient Selection for First-Line Osimertinib Monotherapy in Advanced EGFR-Positive NSCLC Oncodaily
• Efficacy and Safety of Immune Checkpoint Inhibitors Combined With Chemoradiotherapy in Limited-Stage Small Cell Lung Cancer CancerNetwork

20:001 report

• Lung Cancer in Teenagers: The Physicians’ Perspective Medscape

19:00nothing heard

18:00nothing heard

17:00nothing heard

16:00nothing heard

15:00nothing heard

14:00nothing heard

13:00nothing heard

12:00nothing heard

11:00nothing heard

10:001 report

• Study identifies potential treatment target for aggressive lung tumors News-Medical

09:00nothing heard

08:00nothing heard

07:00nothing heard

06:001 report

• Monitoring Anemia and Optimizing Regimen Selection in Resectable NSCLC CancerNetwork

05:00nothing heard

04:003 reports

• Why so many people still are not screened for lung cancer Oman Observer
• How do patients respond to lung cancer screening false positives? | CHEST 2026 Managed Healthcare Executive
• Early Screening, Targeted Treatments Improve Lung Cancer Survival Respiratory Therapy

19:001 report

• Lung cancer: new approach to reduce radiation-related damage healthcare-in-europe.com

18:00nothing heard

17:00nothing heard

16:001 report

• Integrative transcriptomic and machine-learning analysis of the STAT1–GOLM1 axis in lung adenocarcinoma and small-molecule inhibitor discovery Nature

15:00nothing heard

14:00nothing heard

13:00nothing heard

12:00nothing heard

11:00nothing heard

10:00nothing heard

09:005 reports

• Who should be getting annual cancer screenings? WGN Radio 720
• I’m an oncologist. Here’s what non-smokers need to know about lung cancer NZ Herald
• Pulmonary Nodules: Who Needs PET-CT or a Biopsy? Medscape
• Why So Many People Still Are Not Screened for Lung Cancer The New York Times
• Lung cancer can grow silently for years, here’s who qualifies for screening Fox News

08:00nothing heard

07:00nothing heard

06:00nothing heard

05:00nothing heard

04:00nothing heard

03:002 reports

• Jarushka Naidoo: New Developments in Lung Cancer Radiotherapy Highlighted at AILCC26 Oncodaily
• ArriVent Announces Cancer Cell Publication Highlighting Firmonertinib in EGFR PACC-Mutant Non-Small Cell Lung Cancer StreetInsider

02:002 reports

• Lung Cancer Foundation of America Calls for Expanded Screening Eligibility Following Pope Leo XIV's Lung Cancer Diagnosis and Surgery The Manila Times
• Targeting NDUFS2-mediated mitochondrial hyperfunction disrupts energy homeostasis and Akt-mTOR signaling in NSCLC Nature